Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?

Rizvi S, Borad MJ.

J Gastrointest Oncol. 2016 Oct;7(5):789-796. Review.

2.

Chronic myelogenous leukemia-like hematological malignancy with t(8;22) in a 26-year-old pregnant woman: A case report.

Qin YW, Yang YN, Bai P, Wang C.

Oncol Lett. 2016 Jun;11(6):4131-4133. Epub 2016 Apr 27.

3.

Two FGF Receptor Kinase Molecules Act in Concert to Recruit and Transphosphorylate Phospholipase Cγ.

Huang Z, Marsiglia WM, Basu Roy U, Rahimi N, Ilghari D, Wang H, Chen H, Gai W, Blais S, Neubert TA, Mansukhani A, Traaseth NJ, Li X, Mohammadi M.

Mol Cell. 2016 Jan 7;61(1):98-110. doi: 10.1016/j.molcel.2015.11.010. Epub 2015 Dec 10. Erratum in: Mol Cell. 2016 Jan 21;61(2):324.

4.

Fibroblast growth factor receptor 1 promotes MG63 cell proliferation and is associated with increased expression of cyclin-dependent kinase 1 in osteosarcoma.

Zhou W, Zhu Y, Chen S, Xu R, Wang K.

Mol Med Rep. 2016 Jan;13(1):713-9. doi: 10.3892/mmr.2015.4597. Epub 2015 Nov 23.

5.

FGFR1OP2-FGFR1 induced myeloid leukemia and T-cell lymphoma in a mouse model.

Qin H, Wu Q, Cowell JK, Ren M.

Haematologica. 2016 Mar;101(3):e91-4. doi: 10.3324/haematol.2015.137695. Epub 2015 Nov 20. No abstract available.

6.

Targeting RTK Signaling Pathways in Cancer.

Regad T.

Cancers (Basel). 2015 Sep 3;7(3):1758-84. doi: 10.3390/cancers7030860. Review.

7.

Fibroblast growth factor (FGF) signaling in development and skeletal diseases.

Teven CM, Farina EM, Rivas J, Reid RR.

Genes Dis. 2014 Dec 1;1(2):199-213.

8.

DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors.

Huang Z, Tan L, Wang H, Liu Y, Blais S, Deng J, Neubert TA, Gray NS, Li X, Mohammadi M.

ACS Chem Biol. 2015 Jan 16;10(1):299-309. doi: 10.1021/cb500674s. Epub 2014 Oct 27.

9.

Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers.

Tiong KH, Mah LY, Leong CO.

Apoptosis. 2013 Dec;18(12):1447-68. doi: 10.1007/s10495-013-0886-7. Review.

10.

Dysregulated signaling pathways in the development of CNTRL-FGFR1-induced myeloid and lymphoid malignancies associated with FGFR1 in human and mouse models.

Ren M, Qin H, Kitamura E, Cowell JK.

Blood. 2013 Aug 8;122(6):1007-16. doi: 10.1182/blood-2013-03-489823. Epub 2013 Jun 18.

11.

Allogeneic Hematopoietic Stem Cell Transplantation for a BCR-FGFR1 Myeloproliferative Neoplasm Presenting as Acute Lymphoblastic Leukemia.

Haslam K, Langabeer SE, Kelly J, Coen N, O'Connell NM, Conneally E.

Case Rep Hematol. 2012;2012:620967. doi: 10.1155/2012/620967. Epub 2012 Oct 2.

12.

Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome.

Chase A, Bryant C, Score J, Cross NC.

Haematologica. 2013 Jan;98(1):103-6. doi: 10.3324/haematol.2012.066407. Epub 2012 Aug 8.

13.

GAB2--a scaffolding protein in cancer.

Adams SJ, Aydin IT, Celebi JT.

Mol Cancer Res. 2012 Oct;10(10):1265-70. doi: 10.1158/1541-7786.MCR-12-0352. Epub 2012 Aug 7. Review.

14.

Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities.

Ren M, Qin H, Ren R, Cowell JK.

Leukemia. 2013 Jan;27(1):32-40. doi: 10.1038/leu.2012.188. Epub 2012 Jul 11.

15.

Acute progression of BCR-FGFR1 induced murine B-lympho/myeloproliferative disorder suggests involvement of lineages at the pro-B cell stage.

Ren M, Tidwell JA, Sharma S, Cowell JK.

PLoS One. 2012;7(6):e38265. doi: 10.1371/journal.pone.0038265. Epub 2012 Jun 6.

16.

Gab adapter proteins as therapeutic targets for hematologic disease.

Verma S, Vaughan T, Bunting KD.

Adv Hematol. 2012;2012:380635. doi: 10.1155/2012/380635. Epub 2011 Dec 14.

17.

Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases.

Ren M, Qin H, Ren R, Tidwell J, Cowell JK.

Cancer Res. 2011 Dec 1;71(23):7312-22. doi: 10.1158/0008-5472.CAN-11-1109. Epub 2011 Sep 21.

18.

Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease.

Ren M, Cowell JK.

Blood. 2011 Jun 23;117(25):6837-47. doi: 10.1182/blood-2010-07-295725. Epub 2011 Apr 28.

19.
20.

Function, regulation and pathological roles of the Gab/DOS docking proteins.

Wöhrle FU, Daly RJ, Brummer T.

Cell Commun Signal. 2009 Sep 8;7:22. doi: 10.1186/1478-811X-7-22.

Supplemental Content

Support Center